Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OnKure Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OnKure Therapeutics's regulatory disclosures and financial reporting.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small automatic share sale tied to equity compensation. He sold 86 shares of Class A Common Stock on June 22, 2026 at a weighted average price of $4.3963 per share to cover tax withholding obligations from vested restricted stock units under the 2023 RSU Equity Incentive Plan. Following this tax-related sale, he holds 11,247 shares directly, including 4,000 shares acquired through the company’s 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics, Inc.’s Chief Financial Officer Jason A. Leverone reported an automatic sale of 303 shares of Class A Common Stock at a weighted average price of $4.3963 per share. The shares were sold to cover tax withholding obligations tied to vesting RSUs. After this transaction, he directly holds 18,802 shares, including 3,105 shares acquired through the 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics director Edward T. Mathers received a stock option grant representing 7,650 shares of Class A Common Stock. The option has an exercise price of $4.30 per share and expires on June 3, 2036. All 7,650 options will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual meeting of stockholders, contingent on his continued service.
OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock. The options have an exercise price of $4.3000 per share and expire on June 3, 2036. According to the vesting terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer's next annual meeting of stockholders, provided he continues as a service provider through the vesting date. Following this grant, he holds 1,275 derivative securities directly in this option award.
OnKure Therapeutics director Andrew John Phillips received a grant of stock options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share. The options vest 100% on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, contingent on his continued service, and expire on June 3, 2036.
OnKure Therapeutics, Inc. director Valerie Malyvanh Jansen received a grant of stock options covering 7,650 shares of Class A Common Stock. The options have an exercise price of $4.30 per share and expire on June 3, 2036.
All 7,650 option shares will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, if she continues as a service provider through that date. Following this grant, she holds 7,650 options directly.
OnKure Therapeutics director Michael G. Grey received a grant of 7,650 stock options to purchase Class A common stock at an exercise price of $4.30 per share. These options vest 100% on the earlier of June 4, 2027 or the day before the company’s next annual stockholder meeting, provided he continues as a service provider, and expire on June 3, 2036.
OnKure Therapeutics director R. Michael Carruthers received a new stock option grant. On June 4, 2026, he was granted options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share.
All 7,650 option shares will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this grant, he holds options for 7,650 shares directly, with an expiration date of June 3, 2036.
OnKure Therapeutics held its 2026 annual stockholder meeting and approved amendments to its 2024 Equity Incentive Plan. The plan now includes a one-time increase of 3,231,638 shares of common stock, described as approximately 8% of outstanding shares, reserved for equity awards.
The annual “evergreen” feature will continue to add up to 5% of outstanding shares each year, but the prior numerical cap of 2,407,100 shares has been removed, and the number of shares eligible for incentive stock options is now limited. Shareholders also elected three Class II directors to serve until the 2029 annual meeting, ratified KPMG LLP as independent auditor for 2026, and formally approved the amended and restated 2024 Equity Incentive Plan.
OnKure Therapeutics reports ownership disclosures by the BVF group. As of May 27, 2026, the Reporting Persons disclose beneficial ownership aggregating 2,134,908 Shares of Class A Common Stock and hold pre-funded warrants exercisable for an aggregate of 2,147,534 Shares, subject to the 4.9% Pre-Funded Warrants Blocker.
The filing ties percentages to a base of 40,395,480 Shares outstanding as of May 4, 2026, showing individual reported stakes: BVF 1,095,373 Shares (≈ 2.7%), BVF2 854,705 Shares (≈ 2.1%) and Trading Fund OS 153,595 Shares (<1%). The Pre-Funded Warrants are exercisable immediately but currently blocked by the 4.9% limit.